How much of Aurinia Pharmaceuticals’ revenue comes from haram?

Aurinia Pharmaceuticals develops therapeutics against rare autoimmune and kidney-related diseases.

Aurinia earns its revenue primarily from the following revenue sources: 

  • Product Revenue:

Includes revenue generated from selling LUPKYNIS to treat patients with active lupus nephritis.

  • Collaboration and License Agreements:

Includes revenue generated from the license agreement with Otsuka Pharmaceutical to develop and commercialize oral LUPKYNIS.

The contributions from each of Aurinia’s revenue segments in their Q2 2021 report were as follows:

Practical Islamic Finance concludes:

None of Aurinia’s revenue comes from anything inherently haram.

Does Aurinia Pharmaceuticals rely on interest to operate?

Year-to-Date
for period ended
6/30/2021
Fiscal year
ended
12/31/2020
Fiscal year
ended
12/31/2019
Interest Income $314$1,516$2,702
Total Revenue$7,534$50,118$318
Interest Expense
Total Expenses$105,211$154,408$91,261
Interest Income / Revenue4.17%3.02%849.69%
Interest Expense / Total Expense
*Numbers in thousands, U.S. dollars

Practical Islamic Finance concludes: 

Riba is used but not currently relied upon in Aurinia Pharmaceuticals’ operations.

What is Aurinia Pharmaceuticals’ Environmental, Social, and Governance (ESG) Impact?

Environment

No notable environmental highlights.

Social

According to lupkynis.com, nearly 1 out of 2 people with lupus develop lupus nephritis over time. 

Until recently, there were no FDA-approved treatments specifically for lupus nephritis. 

Aurinia has a positive impact on patients living with the disease, preventing them from developing serious health problems, including permanent kidney damage and kidney failure. 

Governance

No notable governance highlights.

Practical Islamic Finance concludes: 

Aurinia has a net positive ESG impact. 

Comfort Rating 

From Aurinia’s business, financial, and ESG reviews, Practical Islamic Finance rates Aurinia stock as: 

Comfortable to invest in from a halal perspective.

Sources

Aurinia’s 2020 Annual Report 

Aurinia’s 2021 Q2 10Q 

Lupkynis™ (voclosporin): An Option for Lupus Nephritis